<DOC>
	<DOCNO>NCT01474889</DOCNO>
	<brief_summary>The Investigator final phase study search Hypo-AWARE Type 1 diabetic control group ( Group 2 ) . The primary goal Group 2 study ; demonstrate hormone Type 1 diabetic react hypoglycemic non-hypoglycemic event . Enrollment Group 1 ( Hypo-Unaware ) Group 3 ( Non-diabetic ) complete . This study design determine real-time continuous glucose monitor ( RT-CGM ) reverse defective Glucose counter regulation hypoglycemia unawareness long stand type 1 diabetes .</brief_summary>
	<brief_title>Glucose Counterregulation Long Standing Type 1 Diabetes</brief_title>
	<detailed_description>The present protocol design determine whether strict hypoglycemia avoidance real-time continuous glucose monitoring ( RT-CGM ) , restore endogenous glucose production response hypoglycemia patient long stand disease . Twelve subject long stand type 1 diabetes complicate hypoglycemia unawareness underwent assessment endogenous glucose production response insulin-induced hypoglycemia use paired hyperinsulinemic eu- hypoglycemic clamp stable glucose isotope infusion 6 18 month follow initiation RT-CGM . The primary analysis change endogenous glucose production response 6 month follow initiation RT-CGM , secondary analysis consider persistence change 18 month . The clinical significance determine change endogenous glucose production response insulin-induced hypoglycemia determine comparison response obtain use paired hyperinsulinemic eu- hypoglycemic clamp one occasion match control group 12 subject long-standing type 1 diabetes hypoglycemia unawareness ( GROUP 2 ) match control group 12 nondiabetic subject ( GROUP 3 ) . The Investigator ONLY recruit GROUP 2 . Enrollment Group 1 ( Hypo-Unaware ) Group 3 ( Non-diabetic ) complete . Hypoglycemia major barrier achievement adequate glycemic control patient insulin-dependent diabetes . Type 1 diabetic patient absolute insulin deficiency ( C-peptide negative ) great risk experience severe hypoglycemic event near total destruction insulin produce islet β-cells produce associate defect glucagon secretion neighbor α-cells . Such patient depend sympathoadrenal system final defense hypoglycemia , unfortunately , recurrent episode hypoglycemia blunt sympathoadrenal activation produce syndrome hypoglycemia unawareness associate twenty-fold increase risk life-threatening hypoglycemia . Without intact islet sympathoadrenal ( especially epinephrine ) response hypoglycemia , patient increase endogenous ( primarily hepatic ) glucose production prevent correct low blood glucose .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Hypoglycemia</mesh_term>
	<mesh_term>Unconsciousness</mesh_term>
	<criteria>Key Inclusion Criteria GROUP 2 ( Group 1 Group 3 complete ) 1 . Male female subject age 25 70 year . 2 . Able provide write informed consent comply procedure study protocol . 3 . Clinical history compatible type 1 diabetes disease onset &lt; 40 year age 4 . Insulindependent &gt; 10 year 5 . Absent Cpeptide ( &lt; 0.3 ng/mL ) . 6 . Involvement intensive diabetes management define use basalbolus insulin analog delivery multidose injection ( MDI ) continuous subcutaneous insulin infusion ( CSII ) together selfmonitoring blood glucose value four time daily , without continuous glucose monitoring ( CGM ) , direction endocrinologist , diabetologist , diabetes nurse practitioner least 3 clinical evaluation previous 12 month . 7 . Intact hypoglycemia awareness indicate Clarke score 3 less . 8 . No episode severe hypoglycemia past 3 year . Key Exclusion Criteria 3 group 1 . Body mass index ( BMI ) great 30 kg/m2 . 2 . Insulin requirement 1.0 IU/kg/day . 3 . HbA1c great 10 % . 4 . Untreated proliferative diabetic retinopathy . 5 . SBP great 160 mmHg DBP great 100 mmHg . 6 . Glomerular filtration rate ( GFR ) less 55 ml/min/1.73 msquared 7 . Positive pregnancy test , presently breastfeed , unwillingness use effective contraceptive measure duration study . 8 . Baseline hemoglobin le 11 g/dl woman less than12 g/dl men . 9 . Severe coexist cardiac disease 10 . Persistent elevation liver function test great 1.5 upper normal limit 11 . Hyperlipidemia despite medical therapy 12 . Receiving treatment medical condition require chronic use systemic steroid 13 . Presence seizure disorder attributable hypoglycemia . 14 . Untreated hypothyroidism , Addisons disease , Celiac disease . 15 . Treatment antidiabetic medication insulin within 4 week enrollment . 16 . Use RTCGM ( continuous glucose monitor ) within last 4 week . Nondiabetic patient need meet glucose criterion .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Hypoglycemia , Unawareness , RT-CGM , Type 1 Diabetes</keyword>
</DOC>